NAGE (Niagen Bioscience Inc) Stock Financials & Earnings

NAGENiagen Bioscience Inc

Mkt Cap$423M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$129M

Net Income (TTM)$17M

EPS (TTM)$0.20

Free Cash Flow (TTM)$13M

Gross Margin64.3%

Op. Margin11.0%

Net Margin13.4%

FCF Margin10.2%

P/S Ratio (TTM)3.3x

P/E Ratio (TTM)24.4x

YoY Rev Growth+29.9%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$23M	$14M	-$2M
Q2 23	$20M	$12M	-$2M
Q3 23	$19M	$12M	-$1M
Q4 23	$21M	$13M	-$168K
Q1 24	$22M	$13M	-$731K
Q2 24	$23M	$14M	-$256K
Q3 24	$26M	$16M	$2M
Q4 24	$29M	$18M	$7M
Q1 25	$30M	$19M	$5M
Q2 25	$31M	$20M	$3M
Q3 25	$34M	$22M	$4M
Q4 25	$34M	$22M	$2M

Revenue Breakdown

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$1M	$6M	$8M	—
Q2 23	$1M	$7M	$6M	—
Q3 23	$1M	$6M	$6M	—
Q4 23	$1M	$5M	$7M	—
Q1 24	$2M	$5M	$7M	—
Q2 24	$1M	$6M	$7M	—
Q3 24	$1M	$6M	$7M	—
Q4 24	$1M	$1M	$9M	—
Q1 25	$1M	$5M	$8M	—
Q2 25	$2M	$7M	$8M	—
Q3 25	$2M	$7M	$9M	—
Q4 25	$2M	—	—	$18M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$23M	$0	$23M
Q2 23	$26M	$0	$26M
Q3 23	$27M	$0	$27M
Q4 23	$27M	$0	$27M
Q1 24	$27M	$0	$27M
Q2 24	$28M	$0	$28M
Q3 24	$32M	$0	$32M
Q4 24	$45M	$0	$45M
Q1 25	$55M	$0	$55M
Q2 25	$60M	$0	$60M
Q3 25	$64M	$0	$64M
Q4 25	$65M	$0	$65M

Shares Outstanding